OR WAIT null SECS
December 04, 2023
Article
For This Year in Medicine, CGTLive looks back at a landmark first approval, the new treatment opportunities it has provided, and the unmet needs in the field it has brought to light.
December 16, 2022
With several newly approved therapies hitting the market and an overflowing pipeline, the FDA has stepped in to help keep the burgeoning world of biotech on track.
November 23, 2022
The BLA was supported by positive data from 54 patients with hemophilia B in the pivotal phase 3 HOPE-B trial.
August 17, 2022
“The approval of ZYNTEGLO marks a watershed moment for the field of gene therapy," Andrew Obenshain, CEO of Bluebird Bio says.